Compare ARDX & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | AFYA |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2014 | 2019 |
| Metric | ARDX | AFYA |
|---|---|---|
| Price | $5.78 | $14.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $10.65 | ★ $18.63 |
| AVG Volume (30 Days) | ★ 2.7M | 84.1K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | ★ 1.55% |
| EPS Growth | N/A | ★ 25.39 |
| EPS | N/A | ★ 1.50 |
| Revenue | $398,234,000.00 | ★ $681,742,784.00 |
| Revenue This Year | $22.77 | $14.67 |
| Revenue Next Year | $28.02 | $7.89 |
| P/E Ratio | ★ N/A | $9.97 |
| Revenue Growth | ★ 58.12 | 14.07 |
| 52 Week Low | $3.21 | $13.47 |
| 52 Week High | $6.78 | $19.90 |
| Indicator | ARDX | AFYA |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 56.50 |
| Support Level | $5.63 | $14.13 |
| Resistance Level | $6.04 | $14.97 |
| Average True Range (ATR) | 0.24 | 0.31 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 17.31 | 92.40 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.